60
603309.SHG Well Lead Med Co Ltd
- Market cap
- CNY 3.22B
- P/E
- 92.0x
- P/B
- 1.72x
- ROE
- 10.8%
- Dividend yield
- 4.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603309.SHG undervalued?
Graham number603309.SHG trades 165.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Well Lead Med Co Ltd fundamental analysis
No fundamental analysis for Well Lead Med Co Ltd yet.
Well Lead Med Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Well Lead Med Co Ltd
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, urethral and ureteral dilation, and stone retrieval bas…
Full company profileWell Lead Med Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Well Lead Med Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 515M | 630M | 746M | 994M | 1.13B | 1.12B | 1.36B | 1.39B | 1.51B | 1.63B | 1.62B |
| Gross Profit | 192M | 214M | 262M | 436M | 493M | 472M | 578M | 625M | 663M | 730M | 683M |
| Operating Income | 85.2M | 72.3M | 69.6M | 147M | 198M | 143M | 207M | 239M | 265M | 305M | 288M |
| EBITDA | 114M | 102M | 101M | 205M | 249M | 198M | 270M | 310M | 338M | 239M | 262M |
| Net Income | 79.2M | 64.6M | 65.4M | 121M | 153M | 106M | 167M | 192M | 219M | 76.3M | 198M |
| EPS | 0.31 | 0.25 | 0.25 | 0.47 | 0.59 | 0.41 | 0.57 | 0.66 | 0.75 | 0.26 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 973M | 1.01B | 1.41B | 1.46B | 1.49B | 2.13B | 2.38B | 2.61B | 2.84B | 2.86B | 2.82B |
| Total Liabilities | 109M | 111M | 474M | 419M | 345M | 541M | 644M | 768M | 938M | 1.08B | 977M |
| Shareholders' Equity | 857M | 892M | 927M | 1.03B | 1.13B | 1.58B | 1.72B | 1.82B | 1.88B | 1.76B | 1.83B |
| Cash & Short-term Investments | 111M | 135M | 149M | 173M | 162M | 635M | 704M | 447M | 480M | 254M | 272M |
| Total Debt | - | - | 258M | 225M | 134M | 241M | 260M | 377M | 467M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 85.3M | 74.3M | 89.9M | 179M | 228M | 187M | 391M | 234M | 306M | 330M | - |
| Capital Expenditure | 68.9M | 71.1M | 78.7M | 113M | 92.5M | 109M | 181M | 358M | 316M | 206M | 144M |
| Free Cash Flow | 16.4M | 3.23M | 11.2M | 66.3M | 136M | 78.0M | 210M | -135M | -9.47M | 124M | 166M |
| Ratios | |||||||||||
| ROE | 9.2% | 7.2% | 7.1% | 11.8% | 13.5% | 6.7% | 9.7% | 10.6% | 11.6% | 4.3% | 10.8% |
| ROA | 8.1% | 6.4% | 4.6% | 8.3% | 10.3% | 5.0% | 7.0% | 7.4% | 7.7% | 2.7% | 7.0% |
| Net Profit Margin | 15.4% | 10.2% | 8.8% | 12.2% | 13.5% | 9.5% | 12.2% | 13.9% | 14.5% | 4.7% | 12.2% |
| Debt to Equity | - | - | 0.28x | 0.22x | 0.12x | 0.15x | 0.15x | 0.21x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Well Lead Med Co Ltd dividends
- Dividend yield
- 4.94%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 208.6%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 159M | 0.55 | 208.6% |
| 2024 | CNY 156M | 0.53 | 70.9% |
| 2023 | CNY 107M | 0.37 | 55.5% |
| 2022 | CNY 39.6M | 0.14 | 23.8% |
| 2021 | CNY 52.0M | 0.20 | 49.0% |
| 2020 | CNY 40.0M | 0.15 | 26.1% |
| 2019 | CNY 20.0M | 0.08 | 16.5% |
| 2018 | CNY 30.0M | 0.12 | 45.9% |
| 2017 | CNY 30.0M | 0.11 | 46.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 25, 2020.
Who owns Well Lead Med Co Ltd
- Insiders 51.15%
- Institutions 5.19%
- Public & others 43.66%
- Shares outstanding 292M
- Free float 143M
Well Lead Med Co Ltd company profile
- Company name
- Well Lead Med Co Ltd
- Ticker
- 603309.SHG
- ISIN
- CNE1000021C2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,849
- Fiscal year end
- December
- Address
- 47 Guomao Avenue South, Guangzhou, China, 511434
- Phone
- 86 20 8475 8878
- Website
- wellead.com
About Well Lead Med Co Ltd
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, urethral and ureteral dilation, and stone retrieval basket; anesthesia products, comprising endotracheal tubes, intubation accessories, laryngeal masks, endobronchial and tracheostomy tubes, anesthesia breathing circuits and accessories, and nasopharyngeal and oropharyngeal airway products. The company also offers respiratory products, including oxygen and aerosol therapy products, and capnography mask and cannula products; drainage/suction/gastroenterology products, such as drainage systems, Yankauer handles, suction catheters, and stomach and feeding tubes; hemodialysis blood tubing set; home care products, including male external catheter and convicath intermittent catheter; and ambulatory infusion pump for pain management. Well Lead Medical Co., Ltd. was founded in 1998 and is based in Guangzhou, China.
Well Lead Med Co Ltd management
5- Mr. Guangyuan HanVice Chairman & GM · born 1964
- Ms. Yimin ZhuCFO & Accounting Supervisor · born 1980
- Ms. Yungui ChenDeputy General Manager · born 1975
- Mr. Song Feng DuanDeputy GM & Director · born 1968
- Mr. Bin ChenDeputy GM & Board Secretary · born 1980